Barclays’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Barclays’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-714	Closed	-$157K	–	7453
2018 Q3	$157K	Buy	+714	New	+$1.71M	﹤0.01%	5190
2015 Q3	–	Sell	-6	Closed	-$9K	–	7128
2015 Q2	$9K	Buy	+6	New	+$8.53K	﹤0.01%	6156
2014 Q3	–	Sell	-13	Closed	-$18K	–	7866
2014 Q2	$18K	Sell	13 -1	-7%	-$1.98K	﹤0.01%	6572
2014 Q1	$20K	Buy	14 +1	+8%	+$2.49K	﹤0.01%	6609
2013 Q4	$18K	Sell	13 -35	-73%	-$80.1K	﹤0.01%	6771
2013 Q3	$133K	Buy	48 +24	+100%	+$119K	﹤0.01%	5396
2013 Q2	$222K	Buy	+24	New	+$185K	﹤0.01%	5068

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barclays's ONCT Position: Q3 2022 in Review

Barclays sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 181 shares — an estimated $4K sold.

Barclays first reported a position in ONCT in Q2 2013 and held it in 17 quarters. The position peaked at $496K in Q2 2013. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

Barclays reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Barclays sold 181 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
Barclays first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
Barclays's Oncternal Therapeutics, Inc. Common Stock position peaked at $496K in Q2 2013.
61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.